Provider briefing: Climara Pro supply constraints in 2026

If your patients have been calling about Climara Pro backorders, you're seeing the clinical impact of a supply issue that began in late 2023 and has persisted into 2026. This briefing covers what's happening with Climara Pro supply, how it affects prescribing decisions, and what resources are available to help your patients maintain continuity of care.

Timeline of the Climara Pro supply disruption

The current Climara Pro supply situation didn't start overnight. Here's how it evolved:

• Late 2023: Bayer discontinued the Climara (estradiol-only) transdermal patch in several international markets, including Australia. This shifted demand toward remaining Bayer products, including Climara Pro, and toward competing brands.
• 2024: Increased patient demand for transdermal HRT — driven by updated menopause treatment guidelines, media attention, and patient preference for non-oral delivery — further strained supply. Multiple manufacturers of estradiol patches reported production delays related to adhesive component sourcing and quality control.
• 2025: Intermittent availability persisted. Climara Pro was not listed on the FDA Drug Shortage Database as a formal shortage, but pharmacies across the U.S. reported inconsistent supply from wholesalers.
• 2026 (current): Supply continues to be intermittent. Bayer has not announced discontinuation of Climara Pro in the U.S., but demand continues to outpace consistent supply to all pharmacy locations.

Prescribing implications

The supply constraints create several challenges for prescribers:

Continuity of care

Patients who have been stable on Climara Pro may face unexpected gaps in therapy. Abrupt discontinuation of combined estrogen-progestin therapy can lead to rebound vasomotor symptoms, sleep disruption, and mood changes. When possible, plan proactive transitions rather than reactive switches.

Formulary considerations

Climara Pro is a brand-name-only product with no generic equivalent. Many insurance formularies place it on a non-preferred tier or require prior authorization and/or step therapy (typically trial of oral HRT first). This adds administrative burden for both the practice and the patient.

Patient communication

Patients are often unaware of why their medication is unavailable and may interpret supply issues as discontinuation. Proactive communication about the situation — and a clear backup plan — can reduce anxiety and prevent treatment gaps.

Current availability picture

Climara Pro availability varies significantly by:

• Geography: Urban areas with more pharmacies tend to have better access than rural regions.
• Pharmacy type: Independent pharmacies and specialty pharmacies may have different wholesaler relationships and better access than major chain pharmacies.
• Fill quantity: 90-day mail-order fills may be more reliably sourced than 30-day retail fills.

The tool Medfinder for Providers allows you to check real-time pharmacy stock levels for Climara Pro in your patient's area, which can help direct them to a pharmacy that currently has supply.

Cost and access considerations

Climara Pro's brand-name-only status means cost is a real barrier for many patients:

• Average cash price: $250–$365/month (4 patches)
• Bayer Savings Card: Saves cash-paying patients up to $75/month; commercially insured patients may pay as little as $25/month
• Bayer Patient Assistance Program: Provides Climara Pro at no cost for eligible uninsured patients at or below 300% of FPL (phone: 866-228-7723)
• Discount cards (GoodRx, SingleCare): May reduce cash price to approximately $238–$260/month

For patients with financial barriers, the savings and assistance guide for Climara Pro covers all available programs.

Tools and resources for your practice

Medfinder for Providers

Medfinder offers real-time pharmacy stock checking. You or your staff can search for Climara Pro availability by location and direct patients to pharmacies that have it in stock. This can save significant phone time for both your office and the patient.

Bayer medical information

For supply-specific questions, providers can contact Bayer Medical Information at 888-842-2937.

Alternative therapy reference

When switching patients off Climara Pro, consider these combination HRT alternatives:

• CombiPatch (estradiol 0.05 mg/norethindrone acetate 0.14 or 0.25 mg/day) — twice-weekly transdermal; brand only
• Activella (estradiol 0.5 mg or 1 mg/norethindrone acetate 0.1 or 0.5 mg) — daily oral; generic available
• Prempro (conjugated estrogens 0.3 or 0.625 mg/MPA 1.5 or 2.5 mg) — daily oral; generic available
• Bijuva (estradiol 1 mg/progesterone 100 mg) — daily oral; brand only; bioidentical combination

Each has a different hormonal profile. When transitioning patients, consider their current symptom control, side effect history, cardiovascular risk factors, and preference for transdermal vs. oral delivery.

For a patient-facing resource you can share: Alternatives to Climara Pro if you can't fill your prescription.

Looking ahead

There is no confirmed timeline for the approval of a generic Climara Pro in the U.S. The transdermal combination patch market remains small, and the manufacturing complexity of patch products makes generic entry slower than for oral medications.

In the meantime, the most effective strategy is proactive planning: identify patients on Climara Pro in your panel, ensure backup prescriptions or alternative plans are documented, and use tools like Medfinder to monitor availability.

Final thoughts

The Climara Pro supply situation is a microcosm of the broader challenges facing hormone therapy access in the U.S. — limited manufacturers, no generics, rising demand, and complex supply chains. As prescribers, the most impactful thing you can do is stay informed, communicate proactively with patients, and have backup plans ready.

Additional provider resources:

• How to help your patients find Climara Pro in stock: a provider's guide
• How to help patients save money on Climara Pro: provider's guide
• Climara Pro drug interactions: what to avoid